Clinical Study
Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial
Table 4
Prevalence of fibroid symptoms before, after treatment, 3, 6, and 9 month after treatment according to groups (Data are presented as
(%*)).
| | Fibroid symptoms | 2.5 mg | 5 mg | |
| | Pelvic pain | | | | | Before treatment | 81 (73.6) | 87 (79.1) | .171 | | 3-month treatment | 14 (13.7) | 9 (8.5) | .114 | | 3-month followup | 21 (21.4) | 24 (23.1) | .389 | | 6-month followup | 31 (33.3) | 24 (23.3) | .060 | | 9-month followup | 33 (36.7) | 25 (25.0) | .041 | | Pelvic pressure | | | | | Before treatment | 74 (67.9) | 73 (65.8) | .369 | | 3-month treatment | 3 (2.9) | 3 (2.8) | .481 | | 3-month followup | 8 (8.2) | 8 (7.7) | .451 | | 6-month followup | 18 (19.5) | 8 (7.8) | .008 | | 9-month followup | 19 (21.1) | 10 (10.0) | .018 | | Urinary symptoms | | | | | Before treatment | 45 (41.3%) | 35 (31.5) | .066 | | 3 month treatment | 3 (2.9) | 3 (2.8) | .481 | | 3-month followup | 7 (7.1) | 8 (7.7) | .454 | | 6-month followup | 12 (12.9) | 7 (6.8) | .074 | | 9-month followup | 12 (13.3) | 6 (6.0) | .042 | | Lumbar pain | | | | | Before treatment | 59 (54.1) | 56 (50.5) | .292 | | 3-month treatment | 3 (2.9) | 1 (1.9) | .147 | | 3-month followup | 4 (4.1) | 9 (8.7) | .093 | | 6-month followup | 15 (16.1) | 10 (9.7) | .089 | | 9-month followup | 17 (18.9) | 11 (11.0) | .062 | | Rectal pain | | | | | Before treatment | 29 (26.6) | 37 (33.3) | .138 | | 3-month treatment | 4 (3.9) | 2 (1.9) | .190 | | 3-month followup | 2 (2.0) | 3 (2.9) | .350 | | 6-month followup | 6 (6.5) | 6 (5.8) | .427 | | 9-month followup | 5 (5.6) | 5 (5.0) | .432 | | Dyspareunia | | | | | Before treatment | 58 (53.2) | 62 (55.9) | .347 | | 3-month treatment | 1 (1.0) | 2 (1.9) | .300 | | 3-month followup | 5 (5.1) | 8 (7.7) | .227 | | 6-month followup | 9 (9.7) | 8 (7.8) | .318 | | 9-month followup | 12 (13.3) | 6 (6.0) | .042 | | Hypermenorrhea | | | | | Before treatment | 79 (71.8) | 73 (66.4) | .191 | | 3-month treatment | 4 (3.9) | 2 (1.9) | .190 | | 3-month followup | 23 (23.5) | 15 (15.4) | .073 | | 6-month followup | 38 (40.9) | 21 (20.4) | <0.001 | | 9-month followup | 37 (41.1) | 24 (24.0) | .005 | | Metrorrhagia | | | | | Before treatment | 15 (13.8) | 22 (19.8) | .115 | | 3-month treatment | 0 | 0 | — | | 3-month followup | 2 (2.0) | 0 | .072 | | 6-month followup | 3 (3.2) | 2 (1.9) | .285 | | 9-month followup | 2 (2.2) | 1 (1.0) | .250 |
|
|
Percentages on the number of subjects in each evaluative period (Figure 1).
**Normal approximation for proportions.
|
